FDA Priority Review Puts Ionis Zilganersen At Center Of Rare-Disease Story [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA Priority Review for its investigational therapy zilganersen for Alexander disease. The designation follows pivotal data indicating meaningful clinical benefit in both children and adults living with this rare neurological condition. Priority Review status is intended to shorten the FDA review timeline for therapies that may offer significant advances in treatment. For investors tracking Ionis Pharmaceuticals, the Priority Review for zilganersen reinforces the company's focus on rare neurological diseases, an area with limited treatment options and high unmet need. Ionis works on RNA targeted medicines, a segment that continues to attract attention as drug makers look for ways to address conditions that have historically lacked therapies. Looking ahead, the Priority Review clock increases attention on upcoming regulatory milestones for Ionis and on how zilganersen may fit into the broader rare disease treatment toolkit if it i
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG) [Yahoo! Finance]Yahoo! Finance
- Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals (IONS) had its price target raised by Barclays PLC from $95.00 to $106.00. They now have an "overweight" rating on the stock.MarketBeat
- Ionis Pharmaceuticals (IONS) had its price target raised by Needham & Company LLC from $103.00 to $105.00. They now have a "buy" rating on the stock.MarketBeat
- Ionis Pharmaceuticals (IONS) had its price target raised by HC Wainwright from $110.00 to $120.00. They now have a "buy" rating on the stock.MarketBeat
IONS
Earnings
- 2/25/26 - Miss
IONS
Sec Filings
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- 3/31/26 - Form 144
- IONS's page on the SEC website